Hui-Ying Liu1, Yen Ta Chen1, Shun-Chen Huang2, Hung-Jen Wang1, Yuan-Tso Cheng1, Chih Hsiung Kang1, Wei Ching Lee1, Yu-Li Su3, Chun-Chieh Huang4, Yin-Lun Chang1, Yao-Chi Chuang1, Hao Lun Luo1, Po Hui Chiang1. 1. Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 2. Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 3. Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 4. Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Abstract
PURPOSE: To assess the association of tumor architecture with cancer recurrence, metastasis, and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) in Taiwan. MATERIALS AND METHODS: Data were collected from 857 patients treated with RNU between January 2005 and August 2016 in our hospital. Pathologic slides were reviewed by genitourinary pathologists. Propensity score weighting was performed for data analysis. RESULTS: Sessile growth pattern was observed in 212 patients (24.7%). Tumor architecture exhibited a significant association with bladder cancer history, chronic kidney disease (CKD), tumor stage, lymph node status, histological grade, lymphovascular invasion, concomitant carcinoma in situ, and the variant type [standardized mean difference (SMD) > 0.1 for all variables before weighting]. In the propensity score analysis, 424 papillary and sessile tumor architecture were analyzed to balance the baseline characteristics between the groups. Tumor architecture was an independent predictor of metastatic disease and CSS (p = 0.033 and p = 0.002, respectively). However, the associations of tumor architecture with bladder and contralateral recurrence were nonsignificant (p = 0.956 and p = 0.844, respectively). CONCLUSIONS: Tumor architecture of UTUC after RNU is associated with established features of aggressive disease and predictors of metastasis and CSS. Assessment of tumor architecture may help identify patients who could benefit from close follow-up or early administration of systemic therapy after RNU. Tumor architecture should be included in UTUC staging after further confirmation.
PURPOSE: To assess the association of tumor architecture with cancer recurrence, metastasis, and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) in Taiwan. MATERIALS AND METHODS: Data were collected from 857 patients treated with RNU between January 2005 and August 2016 in our hospital. Pathologic slides were reviewed by genitourinary pathologists. Propensity score weighting was performed for data analysis. RESULTS: Sessile growth pattern was observed in 212 patients (24.7%). Tumor architecture exhibited a significant association with bladder cancer history, chronic kidney disease (CKD), tumor stage, lymph node status, histological grade, lymphovascular invasion, concomitant carcinoma in situ, and the variant type [standardized mean difference (SMD) > 0.1 for all variables before weighting]. In the propensity score analysis, 424 papillary and sessile tumor architecture were analyzed to balance the baseline characteristics between the groups. Tumor architecture was an independent predictor of metastatic disease and CSS (p = 0.033 and p = 0.002, respectively). However, the associations of tumor architecture with bladder and contralateral recurrence were nonsignificant (p = 0.956 and p = 0.844, respectively). CONCLUSIONS: Tumor architecture of UTUC after RNU is associated with established features of aggressive disease and predictors of metastasis and CSS. Assessment of tumor architecture may help identify patients who could benefit from close follow-up or early administration of systemic therapy after RNU. Tumor architecture should be included in UTUC staging after further confirmation.
Authors: Vitaly Margulis; Ramy F Youssef; Pierre I Karakiewicz; Yair Lotan; Christopher G Wood; Richard Zigeuner; Eiji Kikuchi; Alon Weizer; Jay D Raman; Mesut Remzi; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Wassim Kassouf; Shahrokh F Shariat Journal: J Urol Date: 2010-06-17 Impact factor: 7.450
Authors: Grégory Verhoest; Shahrokh F Shariat; Thomas F Chromecki; Jay D Raman; Vitaly Margulis; Giacomo Novara; Christian Seitz; Mesut Remzi; Morgan Rouprêt; Douglas S Scherr; Karim Bensalah Journal: World J Urol Date: 2011-06-17 Impact factor: 4.226
Authors: Hans-Martin Fritsche; Giacomo Novara; Maximilian Burger; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Kanishka Sircar; Filiberto Zattoni; Tom Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Wolfgang Otto; Wolf Ferdinand Wieland; Pierre I Karakiewicz; Vincenzo Ficarra; Arndt Hartmann; Shahrokh F Shariat Journal: Urol Oncol Date: 2010-10-08 Impact factor: 3.498
Authors: Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey K Ng; Mario Fernández; Theresa M Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat Journal: BJU Int Date: 2008-10-16 Impact factor: 5.588
Authors: Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Weizer; Jay D Raman; Christopher G Wood Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Tzu Shuang Chen; Yen Ta Chen; Hung Jen Wang; Po Hui Chiang; Wen Chou Yang; Wei Ching Lee; Yao Chi Chuang; Yuan Tso Cheng; Chih Hsiung Kang; Wei Chia Lee; Chien Hsu Chen; Yuan Chi Shen; Yi Yang Liu; Hui Ying Liu; Yin Lun Chang; Yu Li Su; Chun Chieh Huang; Hao Lun Luo Journal: Front Oncol Date: 2022-03-15 Impact factor: 6.244